PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 10, 2026Cancer Reports0 citationsOpen Access

Genetic and Immunohistochemical Profiling of Malignant Mesothelioma With Brain Metastasis: A Report of Two Cases

View Full Paper
PHPaul M. HararyStanford UniversityYHYusuke S. HoriStanford UniversityRJRuchit JainBaptist Hospital of Miami

Key Points

  • To report the clinical and genetic characteristics of two patients with brain metastasis from malignant mesothelioma.
  • Described clinical presentations and outcomes of two male patients with brain metastasis from malignant mesothelioma.
  • Conducted genetic profiling using next-generation sequencing to identify mutations in both cases.
  • Detailed treatment approaches, including whole-brain radiotherapy and stereotactic radiosurgery.
  • Case 1 showed a RAD51C missense mutation and underwent WBRT, but passed away 21.25 months post-diagnosis.
  • Case 2 had NF2 and TP53 mutations, responded well to stereotactic radiosurgery, and succumbed to systemic progression 6 months after brain metastasis diagnosis.
  • The TP53 frameshift mutation's unusual presence warrants further investigation into its role in malignant mesothelioma progression.

Abstract

BACKGROUND: Brain metastasis (BM) occurs in < 3% of malignant mesothelioma (MM) cases and is associated with an aggressive disease course. While genomic profiling has provided insight into molecular alterations in MM, the characteristics of MM with brain involvement remain unexplored. Data are particularly limited for MM of pericardial origin, an exceedingly rare tumor which comprises < 1% of mesotheliomas. CASES: We describe the clinical course and genetic profiles of two patients with BM from MM, both of whom exhibited atypical presentations, including neurological symptoms, diagnosis at extremes of age for this condition, and absence of prior asbestos exposure. In Case 1, a 20-25-year-old male with pericardial MM presented for left arm shaking, with brain MRI at this time revealing 14 total lesions, 85.7% of which had vasogenic edema. He underwent whole-brain radiotherapy (WBRT), passing away 21.25 months following initial diagnosis. In Case 2, an 85-90-year-old male reported expressive aphasia and was found to have a large hemorrhagic frontotemporal lesion. He was subsequently diagnosed with pleural MM and received stereotactic radiosurgery (SRS) for management of BM, with a favorable treatment response on follow-up imaging. He succumbed to systemic progression 6 months after diagnosis of BM. Next-generation sequencing identified a missense mutation in RAD51C in Case 1, and NF2 splice-site and TP53 frameshift mutations in Case 2. CONCLUSION: To our knowledge, this represents the first reported genetic profiling of MM with BM. The TP53 frameshift mutation is unusual for MM, and its potential association with rapid disease progression warrants further investigation. Given the aggressive nature of MM, SRS may be preferable to WBRT due to its shorter treatment time and ease of combination with systemic regimens.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Harary et al. (2026) studied this question.

synapsesocial.com/papers/6a0020aec8f74e3340f9b84bhttps://doi.org/10.1002/cnr2.70571
Ask AI
Helpful
Bookmark
Share
View Full Paper